FundaMental Pharma

top of page

From Germany: FundaMental Pharma aims to develop a dual-acting NMDA receptor modulator for treatment resistant depression to improve on the risk profile seen today with esketamine

CEO Dirk Beher describes the unmet need in this setting, and compares and contrasts FundaMental's dual-acting profile with esketamine. The company is working on a €43 million series A aimed to get them all the way to a substantial proof of concept inflection point.

Company News

3 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

From Germany: FundaMental Pharma aims to develop a dual-acting NMDA receptor modulator for treatment resistant depression to improve on the risk profile seen today with esketamine

Follow BiotechTV

Sponsors

Sponsor Spotlight